A GLP-1 program under $300/month is real in 2026 if you pick a structure that doesn't reset in month two. Four PlexusDx protocols stay under the cap at every published dose tier: Microdose GLP-1 Protocol at $129/mo flat, Semaglutide Injection at $189/mo (or $149/mo on the 6-month plan), Tirzepatide Injection at $289/mo (or $249/mo on the 6-month plan), and GLP-Squared at $289/mo (or $249/mo on the 3-month plan) — all cash-pay, all-inclusive, no membership.

What's common, what's serious, and how to manage GLP-1 side effects from FDA-labeled known information — including the boxed warning that applies to both semaglutide and tirzepatide, when to call your provider, and how PlexusDx structures titration and the optional Precision Peptide Genetic Test.

The honest list of GLP-1 options under $200/mo in April 2026 is much shorter than the ads suggest. PlexusDx Microdose GLP-1 Protocol at $129/mo flat is the lowest under-$200 option in this comparison, with PlexusDx Semaglutide Injection at $189/mo month-to-month (or $149/mo on the 6-month plan) as the lowest weekly compounded semaglutide path. FDA-approved Foundayo and the Wegovy pill start at $149/mo at lower doses but escalate with dose; most other “$199 GLP-1” ads are first-month-only promos that jump to $249–$349 on refill.

Wellness stipends typically reimburse GLP-1 programs through receipt upload, not direct employer billing. PlexusDx accepts payment from cards issued under wellness stipend and LSA programs (Compt, Forma, Espresa, Fringe, Benepass, PeopleKeep) and provides itemized receipts — but does not bill employers directly. Stipend eligibility depends on your employer's plan language, especially around “FDA-approved” vs “prescription medication” phrasing for compounded GLP-1s.

Pennsylvania Medicaid cut GLP-1 coverage for adult weight loss on January 1, 2026. This guide walks the legal cash-pay telehealth options that ship to PA, the compounded vs FDA-approved branded distinction, real annualized costs, and where PlexusDx Microdose GLP-1 ($129/mo), Semaglutide Injection ($189/mo), and Tirzepatide Injection ($289/mo) sit relative to Eden, Ro, TrimRx, Willow, and MEDVi — with the optional Precision Peptide Genetic Test adding pathway-level genetic context before week one.

Ohio's GLP-1 coverage fractured in 2025-2026 — State of Ohio employee plan, OSU Health Plan, and Ohio Medicaid all narrowed weight-loss GLP-1 access. This guide walks the cash-pay landscape, Ohio telehealth law, compounded vs FDA-approved options, and where PlexusDx Weight Management Protocols ($129/mo flat to) fit for Ohio residents.

NH Medicaid dropped GLP-1 weight-loss coverage on January 1, 2026. Here’s the cash-pay landscape for New Hampshire residents in 2026 — telehealth eligibility, real prices from $129 to $1,349/mo, compounded vs FDA-approved trade-offs, and where PlexusDx Weight Management Protocols fit.

Kentucky residents have three paths to GLP-1 weight-loss therapy in 2026: brand-name FDA-approved medication (Wegovy, Zepbound) at retail or Lilly Direct, in-person clinical care through systems like UK HealthCare Turfland, and cash-pay compounded telehealth. Kentucky Medicaid does not cover GLP-1 for weight loss. PlexusDx Weight Management Protocols ship to all 120 Kentucky counties from $129/mo flat with no membership fee.

The full 2026 GLP-1 cost map: Wegovy, Ozempic, Zepbound, and Mounjaro at branded list price; Lilly Direct and NovoCare manufacturer self-pay programs ($149–$499/mo); cash-pay compounded telehealth alternatives. PlexusDx Weight Management Protocols span $129/mo to $349/mo with all-inclusive pricing, no membership, all 50 states.

Foundayo's $149 headline is a one-month starter price — the real cash-pay year runs $3,338–$3,738 once you escalate. Compare PlexusDx Microdose GLP-1 ($129/mo flat), Semaglutide Oral ($289/mo), and Tirzepatide Oral ($349/mo) on annualized cost.

Foundayo costs $25/month with covered commercial insurance, $50/month on the Medicare GLP-1 Bridge, or $149-$289/mo self-pay through LillyDirect. Most commercial plans don't cover GLP-1s for weight loss in 2026. Compare cash-pay PlexusDx Weight Management Protocols — Microdose at $129/mo flat, Semaglutide Injection $189/mo, Tirzepatide Injection $289/mo — with no membership fee.

Eden semaglutide reviews split between a 4.4/5 Trustpilot score and BBB billing complaints. We verify Eden's real cost — $99/mo advertised, $198/mo all-in with the required membership (July 2026) — against PlexusDx Semaglutide Injection ($189/mo) and Microdose GLP-1 ($129/mo flat).

Eden vs Ro vs PlexusDx for cash-pay GLP-1: Eden's $298 advertised semaglutide runs $198/mo all-in with its required membership (verified July 2026); Ro pairs a $149/mo membership with branded medication billed on top; PlexusDx runs $129/mo to $349/mo month to month with an optional genetic baseline.

Eden cancellation policy explained: $0 fee, no contract, but refunds hinge on the pharmacy cutoff. Step-by-step portal and email cancellation, the required $99/month membership, and how PlexusDx month-to-month protocols ($129/mo to $349/mo, no membership) avoid the cutoff race.

MEDVi’s compounded plans bundle medication and platform into one price (no separate membership fee); branded Wegovy/Zepbound paths add a separate membership. We reconcile MEDVi’s fee structure, its recurring monthly billing, and where PlexusDx Weight Management Protocols sit at $129/mo to $349/mo with no membership fee on any tier.

Compare the best online tirzepatide providers in 2026 — Ro, Eden, Yucca Health, Willow, Sesame — against the PlexusDx Tirzepatide Injection ($289/mo) and Tirzepatide Oral ($349/mo) Protocols, with a genetic baseline option no other provider offers.

Medicare Part D is statutorily prohibited from covering GLP-1s prescribed solely for weight loss, and manufacturer copay cards are off-limits to Medicare beneficiaries. This guide explains the Medicare GLP-1 Bridge launching July 2026, Part D backdoors for diabetes, CVD, and OSA, and the cash-pay options that work today — including PlexusDx Microdose GLP-1 Protocol at $129/mo flat and Semaglutide Injection at $189/mo month-to-month, or from $149/mo on the 6-month plan.

How PlexusDx Weight Management Protocols compare to the major cash-pay GLP-1 programs in 2026 — Mochi, Eden, MEDVi, Ro, GoodRx Care Direct, NovoCare, and LillyDirect — on price, medication source, membership fees, and total annualized cost.

Compounded tirzepatide provider rankings cycle through MEDVi, Eden, Yucca Health, Willow, and TrimRx. PlexusDx Tirzepatide Injection ($289/mo) and Tirzepatide Oral ($349/mo) compare on price, oversight, and genetic-test personalization.

503A vs 503B compounding pharmacy explained — the regulatory framework, FDA Modernization Act of 1997 and Drug Quality and Security Act of 2013, oversight differences, and a five-step verification checklist for compounded GLP-1 medications.

Are GLP-1 pills safe? Four are FDA-approved in 2026 (Rybelsus, Ozempic tablets, Wegovy tablet, Foundayo). Patient-specific compounded oral GLP-1s through licensed pharmacies are a separate lawful category. No-prescription drops and gummies aren't legitimate. Here's the safety framework, the boxed-warning context, and where PlexusDx oral protocols fit.

A buyer-side read of the seven brand-name GLP-1 telehealth providers (Ro, Walgreens, GoodRx, Hims & Hers, PlushCare, Sesame, WeightWatchers) covering true month-one cost, what each dispenses, and how PlexusDx compounded protocols ($129/mo to $349/mo, all-inclusive, no membership) fit when branded coverage isn't accessible.

How to verify a 503A compounding pharmacy before ordering compounded semaglutide or tirzepatide: eight automatic walk-away triggers, a 10-minute audit using state-board, FDA, PCAB, and NABP databases, and where PlexusDx Weight Management Protocols sit in that framework.

A "GLP agonist" is a drug that switches on the GLP-1 receptor. This PlexusDx explainer starts with what agonism means, then covers the receptor targeted, single-, dual-, and triple-agonist variations, the approved options, shared safety, and the GLP1R genetics underneath.

GLP-1 RA is shorthand for GLP-1 receptor agonist. This guide decodes the abbreviation, explains the hormone and the receptor behind it, lists the medications in the class as of April 2026, covers the shared safety profile, and shows where genetics sit upstream.

Searchers looking for Wegovy weight loss pills want to know whether a swallowable option exists. This page explains the current oral reality, the absorption problem peptides face, and how the pill and injection dose numbers differ, before turning to genetic context.

People searching for Wegovy tablets usually want to know whether a swallowable version exists. This page lays out the current format reality, the absorption hurdles oral peptides face, and how injectable and oral semaglutide compare on dosing and everyday practicality.

Tirzepatide is the generic name, yet no FDA-approved generic tirzepatide product exists as of April 2026. This article untangles the naming paradox, the patent timeline stretching into the mid-2030s, the peptide biosimilar pathway, and the legitimate lower-cost paths that are available to patients now.